News

The latest results from the ongoing tests of AstraZeneca Roxadustat show that the oral drug may be a safe and effective option for patients with myelofibrosis who develop anemia due …

The FDA has approved the widespread use of @Bristol Myers Squibb’s drug Reblozyl for treating anemia in adult patients with beta-thalassemia who require regular blood transfusions and suffer from low-to-intermediate-risk …

Ongoing stage 2a clinical trials for Pfizer‘s Oxbryta (voxelotor) continue to show successful results in pediatric patients. Approved for treating SCD, the oral medication prevents red blood cells from sickle-shaping …

A Phase 2/3 multicenter study of Osivelotor has been approved to proceed by India’s Central Drugs Standard Control Organisation (CDSCO). Aimed at treating Sickle Cell Disease, the drug (GBT021601) has …

A clinical trial led by Dr. Ali Taher at the American University of Beirut Medical Center, shows that Mitapivat has potential benefits for non-transfusion dependent thalassemia patients. Developed by Agios …

Tim Randolph has been recognized by the National Academy of Inventors for his innovative work in developing more accessible diagnostics for sickle cell disease. The research has led to the …

We are happy to see Functional Fluidics expanding to Africa and setting up a new research clinic and laboratory in Nigeria. And we are truly grateful for the significant contributions …

The Department of Health of Puerto Rico has granted authorization to market Endari, an oral powder treatment for sickle cell disease (SCD). The first FDA-backed oral glutamine, Endari has been …

Sickle cell disease affects a significant number of individuals in North Carolina, particularly within the Black community, where about 95 percent of cases are found. This genetic blood disorder not …